Veronica R. Chiesi Brown
ROCHESTER, N.Y. – Rochester Regional Health is the first health system in Western and Central New York to offer UroLift®, an implant that decreases urinary outflow obstruction caused by benign prostatic hyperplasia (BPH) in men 50 years of age or older.
The permanent implant, which holds the lateral lobes of the enlarged prostate open, is a minimally-invasive procedure with durable clinical results. Most patients return home on the same day of treatment without a catheter, and many experience symptom relief in as early as two weeks. Rochester Regional Health urologist John Valvo, M.D., FACS, director of Finger Lakes Urology Institute and robotics medical director for Rochester General Hospital, has already begun performing the procedure on patients.
“Many men suffer from bladder outlet obstruction, caused by BPH. Oftentimes it starts with nuisance-type symptoms, but can progress to a point where they are unable to urinate at all,” said Dr. Valvo.
Treatment for enlarged prostate typically involves medication, which can be difficult to tolerate and can be costly for patients. UroLift® provides a simple alternative that falls between pharmacological and surgical options. Clinical trial data revealed rapid symptom improvement, increased urinary flow rates, and sustained sexual function. UroLift® was approved by the FDA in 2013.
Rochester Regional Health is an integrated health services organization serving the people of Western New York, the Finger Lakes and beyond. The system includes five hospitals; primary and specialty practices, rehabilitation centers, ambulatory campuses and immediate care facilities; innovative senior services, facilities and independent housing; a wide range of behavioral health services; and ACM Medical Laboratory, a global leader in patient and clinical trials. Rochester Regional Health is the region’s second largest employer. Learn more at RochesterRegional.org.